Built on biologics manufacturing expertise, Samsung Biologics integrates
process development, analytical characterization, and manufacturing execution
within a connected operational environment designed to reduce conjugation
complexity, maintain process consistency, and enable reliable scale-up across
bioconjugation programs.
Researchers working in cleanroom
-
*ADC: Antibody-Drug Conjugates
-
Bioconjugation Infrastructure
Our bioconjugation infrastructure in Songdo Campus supports a broad range of conjugation modalities, with a dedicated ADC Facility exclusively built for high potency API (HPAPI) handling operated separately from our other biomanufacturing services to ensure the highest standards of safety and regulatory compliance.
The Songdo Campus features:- Expedited and flexible drug substance (DS) delivery
- Expertise in quality and a proven operational track record
- Integrated systems with established tools and procedures
- Stable supply chain management system
Dedicated ADC Facility
-
Single-use and stainless-steel reactor systems support
bioconjugation processes at scales up to 500 L train, enabling
seamless progression and scale-up from development through
manufacturing.
Integrated laboratories support bioconjugation development,
quality control (QC), and MSAT activities across manufacturing
operations.
Designed for high potency API (HPAPI) handling, the facility
incorporates stringent containment systems engineered to
achieve Occupational Exposure Limits (OELs) below 1 ng/m.
Coordinated Bioconjugation Execution Across Development and Manufacturing
Development, analytical characterization, formulation, and manufacturing activities are coordinated to enable reliable progression
from early development through commercial-scale manufacturing.
Manufactruing-ready Bioconjugation Development
Development strategies are designed to improve process reproducibility, maintain controlled DAR profiles, and prepare programs for reliable manufacturing scale-up.
-
Conjugation
Method, parameter optimization, DAR variation control
-
Analysis
Analytical Method development, Precise Analysis and Characterization
-
Formulation
Stability enhancement and Lyo development
Scalable Manufacturing Execution Across Bioconjugation Operations
Manufacturing operations span antibody preparation, conjugation, purification, formulation, and bulk drug substance manufacturing, to support reliable scale up across bioconjugation programs.
Payload & mAb Prep
- mAb Thawing
- Payload Prep
- UF/DF1
- Reduction
Conjugation
- Conjugation
- Quenching
- UF/DF2
- Chromatography
Formulated Bulk
- UF/DF3
- Formulation & Bulk Fill
Drug Product
- Fill/Finish
Analytical Characterization for Process and Product Understanding
Analytical characterization capabilities support DAR analysis, comparability assessments, and manufacturing consistency across
bioconjugate development and manufacturing activities.
-
Raw Material
- ID for payload-linker
-
IPC Testing
- Protein concentration
-
Chemistry
- DAR
- Residual solvent
- Free drug
-
Biochemistry
- Bioassay
- Antigen binding assay
- Cytotoxidity assay
Samsung Biologics continues to strengthen its bioconjugation
and manufacturing capabilities through strategic investments
supported by the Samsung Life Science Fund.
and manufacturing capabilities through strategic investments
supported by the Samsung Life Science Fund.
AIMEDBIO
Cutting-edge ADC
development technology
development technology
brickbio
Protein engineering
technology for ADCs
technology for ADCs
Related Content